These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20153612)

  • 1. The direct economic cost of pharmacologically-treated diabetes in Italy-2006. The ARNO observatory.
    Marchesini G; Forlani G; Rossi E; Berti A; De Rosa M;
    Nutr Metab Cardiovasc Dis; 2011 May; 21(5):339-46. PubMed ID: 20153612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence, prevalence, costs and quality of care of type 1 diabetes in Italy, age 0-29 years: The population-based CINECA-SID ARNO Observatory, 2002-2012.
    Bruno G; Pagano E; Rossi E; Cataudella S; De Rosa M; Marchesini G; Miccoli R; Vaccaro O; Bonora E
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1104-1111. PubMed ID: 27817991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Under-treatment of migrants with diabetes in a universalistic health care system: the ARNO Observatory.
    Marchesini G; Bernardi D; Miccoli R; Rossi E; Vaccaro O; De Rosa M; Bonora E; Bruno G
    Nutr Metab Cardiovasc Dis; 2014 Apr; 24(4):393-9. PubMed ID: 24462046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004.
    van der Linden MW; Plat AW; Erkens JA; Emneus M; Herings RM
    Value Health; 2009 Sep; 12(6):909-14. PubMed ID: 19508664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relative burden of diabetes complications on healthcare costs: The population-based CINECA-SID ARNO Diabetes Observatory.
    Pagano E; De Rosa M; Rossi E; Cinconze E; Marchesini G; Miccoli R; Vaccaro O; Bonora E; Bruno G
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):944-50. PubMed ID: 27289165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct costs in diabetic and non diabetic people: the population-based Turin study, Italy.
    Bruno G; Picariello R; Petrelli A; Panero F; Costa G; Cavallo-Perin P; Demaria M; Gnavi R
    Nutr Metab Cardiovasc Dis; 2012 Aug; 22(8):684-90. PubMed ID: 21907553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
    von Ferber L; Köster I; Hauner H
    Med Klin (Munich); 2006 May; 101(5):384-93. PubMed ID: 16685485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical burden of diabetes in Italy in 2018: a look at a systemic disease from the ARNO Diabetes Observatory.
    Bonora E; Cataudella S; Marchesini G; Miccoli R; Vaccaro O; Fadini GP; Martini N; Rossi E;
    BMJ Open Diabetes Res Care; 2020 Jul; 8(1):. PubMed ID: 32713842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiological trends and direct costs of diabetes in a Northern Italy area: 2012 health administrative records analysis LHT n. 20 Verona.
    Demurtas J; Alba N; Rigon G; Nesoti MV; Bovo C; Vaona A
    Prim Care Diabetes; 2017 Dec; 11(6):570-576. PubMed ID: 28663023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study.
    Lucioni C; Garancini MP; Massi-Benedetti M; Mazzi S; Serra G;
    Treat Endocrinol; 2003; 2(2):121-33. PubMed ID: 15871548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct health care costs of diabetic patients in Spain.
    Oliva J; Lobo F; Molina B; Monereo S
    Diabetes Care; 2004 Nov; 27(11):2616-21. PubMed ID: 15504995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial treatment of diabetes in Italy. A nationwide population-based study from of the ARNO Diabetes Observatory.
    Bonora E; Cataudella S; Marchesini G; Miccoli R; Vaccaro O; Fadini GP; Martini N; Rossi E;
    Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2661-2668. PubMed ID: 34218990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
    Palmer JL; Goodall G; Nielsen S; Kotchie RW; Valentine WJ; Palmer AJ; Roze S
    Curr Med Res Opin; 2008 May; 24(5):1417-28. PubMed ID: 18400145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.
    Misurski D; Lage MJ; Fabunmi R; Boye KS
    Appl Health Econ Health Policy; 2009; 7(4):245-54. PubMed ID: 19905038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].
    Bierwirth RA; Kohlmann T; Moock J; Holle R; Landgraf W
    Med Klin (Munich); 2010 Nov; 105(11):792-801. PubMed ID: 21136237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.
    Holden SE; Morgan CL; Qiao Q; Jenkins-Jones S; Berni ER; Currie CJ
    Diabetes Obes Metab; 2017 Aug; 19(8):1097-1105. PubMed ID: 28218819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach.
    Marcellusi A; Viti R; Mecozzi A; Mennini FS
    Eur J Health Econ; 2016 Mar; 17(2):139-47. PubMed ID: 25427540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.